 | • レポートコード：MRC309Z7773 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の抗血管新生点眼剤の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の抗血管新生点眼剤市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 抗血管新生点眼剤の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 抗血管新生点眼剤市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症 用途別セグメント ・小売薬局、オンライン薬局、病院薬局 主要な市場プレーヤー ・Gilead Sciences, Inc.、Eyetech Inc.、Becton, Dickinson and Company、Regeneron Pharmaceuticals, Inc.、Genentech, Inc.、Novartis AG、Allergan plc、Bayer AG、Santen Pharmaceutical Co., Ltd.、Shanghai Pharmaceuticals、Johnson & Johnson、Pfizer、Sun Pharma、Otsuka Pharmaceutical Co. Ltd、Daiichi Sankyo、ERC Labs、Medicom Health care、Implant ophthalmic products GmbH、The Geuder Group, MORCHER GmbH、Novamedika 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、抗血管新生点眼剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な抗血管新生点眼剤メーカーの企業概要、2019年～2022年までの抗血管新生点眼剤の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な抗血管新生点眼剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別抗血管新生点眼剤の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの抗血管新生点眼剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での抗血管新生点眼剤市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および抗血管新生点眼剤の産業チェーンを掲載しています。 ・第14、15章では、抗血管新生点眼剤の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 抗血管新生点眼剤の概要 - 種類別分析（2018年vs2022年vs2029年）：近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症 - 用途別分析（2018年vs2022年vs2029年）：小売薬局、オンライン薬局、病院薬局 - 世界の抗血管新生点眼剤市場規模・予測 - 世界の抗血管新生点眼剤生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Gilead Sciences, Inc.、Eyetech Inc.、Becton, Dickinson and Company、Regeneron Pharmaceuticals, Inc.、Genentech, Inc.、Novartis AG、Allergan plc、Bayer AG、Santen Pharmaceutical Co., Ltd.、Shanghai Pharmaceuticals、Johnson & Johnson、Pfizer、Sun Pharma、Otsuka Pharmaceutical Co. Ltd、Daiichi Sankyo、ERC Labs、Medicom Health care、Implant ophthalmic products GmbH、The Geuder Group, MORCHER GmbH、Novamedika ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症 ・用途別分析2018年-2029年：小売薬局、オンライン薬局、病院薬局 ・抗血管新生点眼剤の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・抗血管新生点眼剤のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・抗血管新生点眼剤のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・抗血管新生点眼剤の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・抗血管新生点眼剤の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Anti-angiogenic Ophthalmic Agent market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
This report is a detailed and comprehensive analysis for global Anti-angiogenic Ophthalmic Agent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Anti-angiogenic Ophthalmic Agent market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-angiogenic Ophthalmic Agent market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-angiogenic Ophthalmic Agent market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-angiogenic Ophthalmic Agent market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-angiogenic Ophthalmic Agent
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-angiogenic Ophthalmic Agent market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc. and Genentech, Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Anti-angiogenic Ophthalmic Agent market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Market segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Major players covered
Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implant ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anti-angiogenic Ophthalmic Agent product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-angiogenic Ophthalmic Agent, with price, sales, revenue and global market share of Anti-angiogenic Ophthalmic Agent from 2018 to 2023.
Chapter 3, the Anti-angiogenic Ophthalmic Agent competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-angiogenic Ophthalmic Agent breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Anti-angiogenic Ophthalmic Agent market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-angiogenic Ophthalmic Agent.
Chapter 14 and 15, to describe Anti-angiogenic Ophthalmic Agent sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Anti-angiogenic Ophthalmic Agent
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Myopic Choroidal Neovascularization
1.3.3 Macular Edema
1.3.4 Diabetic Retinopathy
1.3.5 Macular Degeneration
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Retail Pharmacies
1.4.3 Online Pharmacies
1.4.4 Hospital Pharmacies
1.5 Global Anti-angiogenic Ophthalmic Agent Market Size & Forecast
1.5.1 Global Anti-angiogenic Ophthalmic Agent Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Anti-angiogenic Ophthalmic Agent Sales Quantity (2018-2029)
1.5.3 Global Anti-angiogenic Ophthalmic Agent Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Gilead Sciences, Inc.
2.1.1 Gilead Sciences, Inc. Details
2.1.2 Gilead Sciences, Inc. Major Business
2.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Gilead Sciences, Inc. Recent Developments/Updates
2.2 Eyetech Inc.
2.2.1 Eyetech Inc. Details
2.2.2 Eyetech Inc. Major Business
2.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eyetech Inc. Recent Developments/Updates
2.3 Becton, Dickinson and Company
2.3.1 Becton, Dickinson and Company Details
2.3.2 Becton, Dickinson and Company Major Business
2.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
2.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Becton, Dickinson and Company Recent Developments/Updates
2.4 Regeneron Pharmaceuticals, Inc.
2.4.1 Regeneron Pharmaceuticals, Inc. Details
2.4.2 Regeneron Pharmaceuticals, Inc. Major Business
2.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
2.5 Genentech, Inc.
2.5.1 Genentech, Inc. Details
2.5.2 Genentech, Inc. Major Business
2.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Genentech, Inc. Recent Developments/Updates
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
2.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments/Updates
2.7 Allergan plc
2.7.1 Allergan plc Details
2.7.2 Allergan plc Major Business
2.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
2.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Allergan plc Recent Developments/Updates
2.8 Bayer AG
2.8.1 Bayer AG Details
2.8.2 Bayer AG Major Business
2.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
2.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bayer AG Recent Developments/Updates
2.9 Santen Pharmaceutical Co., Ltd.
2.9.1 Santen Pharmaceutical Co., Ltd. Details
2.9.2 Santen Pharmaceutical Co., Ltd. Major Business
2.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
2.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
2.10 Shanghai Pharmaceuticals
2.10.1 Shanghai Pharmaceuticals Details
2.10.2 Shanghai Pharmaceuticals Major Business
2.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
2.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
2.11 Johnson & Johnson
2.11.1 Johnson & Johnson Details
2.11.2 Johnson & Johnson Major Business
2.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
2.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Johnson & Johnson Recent Developments/Updates
2.12 Pfizer
2.12.1 Pfizer Details
2.12.2 Pfizer Major Business
2.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
2.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Pfizer Recent Developments/Updates
2.13 Sun Pharma
2.13.1 Sun Pharma Details
2.13.2 Sun Pharma Major Business
2.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
2.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Sun Pharma Recent Developments/Updates
2.14 Otsuka Pharmaceutical Co. Ltd
2.14.1 Otsuka Pharmaceutical Co. Ltd Details
2.14.2 Otsuka Pharmaceutical Co. Ltd Major Business
2.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
2.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
2.15 Daiichi Sankyo
2.15.1 Daiichi Sankyo Details
2.15.2 Daiichi Sankyo Major Business
2.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
2.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Daiichi Sankyo Recent Developments/Updates
2.16 ERC Labs
2.16.1 ERC Labs Details
2.16.2 ERC Labs Major Business
2.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
2.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 ERC Labs Recent Developments/Updates
2.17 Medicom Health care
2.17.1 Medicom Health care Details
2.17.2 Medicom Health care Major Business
2.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
2.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Medicom Health care Recent Developments/Updates
2.18 Implant ophthalmic products GmbH
2.18.1 Implant ophthalmic products GmbH Details
2.18.2 Implant ophthalmic products GmbH Major Business
2.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
2.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Implant ophthalmic products GmbH Recent Developments/Updates
2.19 The Geuder Group, MORCHER GmbH
2.19.1 The Geuder Group, MORCHER GmbH Details
2.19.2 The Geuder Group, MORCHER GmbH Major Business
2.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
2.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 The Geuder Group, MORCHER GmbH Recent Developments/Updates
2.20 Novamedika
2.20.1 Novamedika Details
2.20.2 Novamedika Major Business
2.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
2.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Novamedika Recent Developments/Updates
3 Competitive Environment: Anti-angiogenic Ophthalmic Agent by Manufacturer
3.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Manufacturer (2018-2023)
3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturer (2018-2023)
3.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Anti-angiogenic Ophthalmic Agent by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Anti-angiogenic Ophthalmic Agent Manufacturer Market Share in 2022
3.4.2 Top 6 Anti-angiogenic Ophthalmic Agent Manufacturer Market Share in 2022
3.5 Anti-angiogenic Ophthalmic Agent Market: Overall Company Footprint Analysis
3.5.1 Anti-angiogenic Ophthalmic Agent Market: Region Footprint
3.5.2 Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
3.5.3 Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Anti-angiogenic Ophthalmic Agent Market Size by Region
4.1.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2029)
4.1.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2029)
4.1.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2029)
4.2 North America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.3 Europe Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.4 Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.5 South America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.6 Middle East and Africa Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
5.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type (2018-2029)
5.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
6.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application (2018-2029)
6.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029)
7 North America
7.1 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
7.2 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
7.3 North America Anti-angiogenic Ophthalmic Agent Market Size by Country
7.3.1 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
7.3.2 North America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
8.2 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
8.3 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country
8.3.1 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
8.3.2 Europe Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Region
9.3.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
10.2 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
10.3 South America Anti-angiogenic Ophthalmic Agent Market Size by Country
10.3.1 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
10.3.2 South America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Anti-angiogenic Ophthalmic Agent Market Size by Country
11.3.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Anti-angiogenic Ophthalmic Agent Market Drivers
12.2 Anti-angiogenic Ophthalmic Agent Market Restraints
12.3 Anti-angiogenic Ophthalmic Agent Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Anti-angiogenic Ophthalmic Agent and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-angiogenic Ophthalmic Agent
13.3 Anti-angiogenic Ophthalmic Agent Production Process
13.4 Anti-angiogenic Ophthalmic Agent Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-angiogenic Ophthalmic Agent Typical Distributors
14.3 Anti-angiogenic Ophthalmic Agent Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer